Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
ChemMedChem · 02.08.2025 · 20 (15)
DOI: 10.1002/cmdc.202500262 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 24.06.2025. Verfasst von Yaxin Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Henan Linker Technology Key Laboratory, College of Advanced Interdisciplinary Science and Technology, Henan University of Technology, NO. 100 Lianhua…. Hauptthemen laut MEDLINE: Immunoconjugates, Drug Design, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 166 Literaturangaben. Gefördert von: Distinguished University Professor Grant (Nanyang Technological University), AcRF Tier 1 grants from the Ministry of Education of Singapore, the Agency for Science, Technology and Research (A∗STAR) under its MTC Individual Research Grants.
Abstract (Originalsprache)
Inspired by the “magic bullet” concept proposed over a century ago, antibody–drug conjugates (ADCs) are developed to enhance cancer therapy by linking monoclonal antibodies to a cytotoxic payload, aiming to overcome the limitations of conventional chemotherapy. To date, 17 ADCs have received regulatory approval for treating both hematologic and solid tumors. Despite their clinical success, developing ADCs with optimal therapeutic potential remains challenging. While selecting the appropriate antibody and cytotoxin is crucial, the linker plays a pivotal role in determining plasma stability and efficient payload release at the tumor site. Over the past decade, advances in linker technology have significantly improved the pharmacokinetics, efficacy, and toxicity profiles of ADCs. This review provides an overview of clinically validated linkers and recent innovations in linker design, focusing on drug release triggers, bioconjugation strategies, the impact of spacers on hydrophilicity, traceless drug release, and linker architecture, as well as a discussion of the bystander effect, offering insights for the rational design of next‐generation ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Linker Technology Key Laboratory, College of Advanced Interdisciplinary Science and Technology, Henan University of Technology, NO. 100 Lianhua Street, Zhengzhou, 450001, China.
- College of Food Science and Engineering, Henan University of Technology, NO. 100 Lianhua Street, Zhengzhou, 450001, China.
- School of Science, Monash University, Jalan Lagoon Selatan, 47500, Selangor, Malaysia.
- Division of Chemistry and Biological Chemistry, School of Chemistry, Chemical Engineering, and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore.
ORCID-Profile: Teck Peng Loh, Huitao Liu
Förderung
- Distinguished University Professor Grant (Nanyang Technological University)
- AcRF Tier 1 grants from the Ministry of Education of Singapore
- the Agency for Science, Technology and Research (A∗STAR) under its MTC Individual Research Grants
- Start-up Grant of Henan University of Technology
- Shenzhen Vaccine Biopharmaceuticals Limited
Zitieren
APA
Lei, Y., Zheng, M., Chen, P., Seng Ng, C., Peng Loh, T., & Liu, H. (2025). Linker Design for the Antibody Drug Conjugates: A Comprehensive Review. ChemMedChem, 20(15). https://doi.org/10.1002/cmdc.202500262
Vancouver
Lei Y, Zheng M, Chen P, Seng Ng C, Peng Loh T, Liu H. Linker Design for the Antibody Drug Conjugates: A Comprehensive Review. ChemMedChem. 2025;20(15). doi:10.1002/cmdc.202500262
BibTeX
@article{Lei2025,
author = {Lei, Yaxin and Zheng, Minglei and Chen, Peng and Seng Ng, Chen and Peng Loh, Teck and Liu, Huitao},
title = {Linker Design for the Antibody Drug Conjugates: A Comprehensive Review},
journal = {ChemMedChem},
year = {2025},
volume = {20},
number = {15},
doi = {10.1002/cmdc.202500262}
}
EUVIMED